The Broad Institute is a new kind of collaborative research institution — uniting two great universities and five leading hospitals, spanning scientific disciplines and drawing on unrivaled scientific platforms. Beyond its own research, the Broad creates and shares its powerful tools and databases openly with the entire international scientific community, propelling a biomedical revolution around the world.

A new era in medicine. The Human Genome Project, completed in 2003, laid the foundation for a new era in medicine — one in which it would be possible to systematically discover the molecular mechanisms of cancer, heart disease, diabetes, autism, schizophrenia, and other diseases. Fulfilling this promise, however, required methods, technology, and scale far beyond the typical academic laboratory.

A new kind of research institute. Launched in 2004, the Broad Institute grew from two different groundbreaking organizations — a flagship center of the Human Genome Project and an innovative institute pioneering new approaches in chemistry and human biology. It defined a new collaborative model for biomedical research — bringing together extraordinary scientists across Harvard, MIT, and the Harvard-affiliated hospitals. Engaging more than 2,000 scientists, the Broad empowers cross-institutional and cross-disciplinary teams to tackle bold challenges that could not be done in traditional settings. It combines medicine, chemistry, biology, computer science, and engineering, and spans small labs and large industrial-style platforms. The Broad’s unique organization is possible because of the unparalleled strength of the Boston biomedical community.
A bold mission. The Broad’s mission is to transform medicine by revealing the fundamental mechanisms of diseases and developing new ways to create medicines to treat them. Broad researchers have pioneered the methods to systematically discover the genes responsible for inherited diseases; the mutations and pathways that drive cancer; the functional elements in the human genome; the biological circuits that underlie cellular responses; and the molecular basis of major infectious diseases. Broad researchers have also pioneered powerful new ways to accelerate the drug-discovery process, including synthesizing chemicals of unprecedented diversity; developing new ways to test candidate drugs on living cells and tissues; creating methods to rapidly identify drug targets; and developing ways to increase the accuracy and efficiency of clinical trials.

Powering a biomedical revolution around the globe. The Broad freely shares its massive databases, powerful computational programs, and comprehensive genomic reagents. More than 100,000 scientists around the world in academia and industry rely on the Broad’s freely available resources to propel their own research. The Broad plays a pivotal role in biomedicine today.

Broad Institute scientists pursue a wide variety of projects that cut across scientific disciplines and institutions. These projects are fueled in part by communities of researchers that come together around shared challenges in major disease areas or scientific disciplines, including:

- Cancer
- Cell Circuits
- Chemical Biology
- Epigenomics
- Genome Sequencing and Analysis
- Infectious Disease
- Medical and Population Genetics
- Metabolism
- Psychiatric Disease

The Institute is also deeply committed to technology and technology development. In-house teams with the expertise and organization to carry out large-scale projects work closely with Broad scientists and other collaborators to tackle problems that cannot be addressed in a typical laboratory. These teams include:

- Genomics
- Imaging
- Metabolite Profiling
- Proteomics
- RNAi
- Technology Labs
- Therapeutics Discovery
- Therapeutics Translation
The ambitious projects undertaken by the Broad Institute would not be possible without the critical support and continued commitment of our donors, research sponsors, and friends. We would like to thank the following individuals and organizations for their investment in improving human health through their support of the Broad Institute:

**Eli and Edythe L. Broad**
Discussions among Los Angeles philanthropists Eli and Edythe L. Broad, MIT, Harvard, and the Harvard-affiliated hospitals shaped the vision for a new kind of research organization and community. The visionary generosity of the Broads ($100 million over ten years, subsequently doubled to $200 million) made it possible to formally announce the Eli and Edythe L. Broad Institute of Harvard and MIT in June 2003 and to launch it in May 2004. In September 2008, the Broads, Harvard, and MIT declared the new model a success. At the same time, the Broads announced that they would endow the institute with an additional $400 million, the largest single gift to a biomedical academic research center to date.

**The Stanley Medical Research Institute**
The Broad Institute’s Stanley Center for Psychiatric Research was established in 2007 with the extraordinary support of a ten-year, $100 million grant from the Stanley Medical Research Institute (SMRI). In April 2011, SMRI extended that support through 2022. The mission of the Stanley Center is to discover the human genes that confer risk for psychiatric disorders and to use this information to develop new diagnostic tests and treatments for these illnesses.

**Instituto Carlos Slim de la Salud**
In 2010, Carlos Slim Helú announced the launch of the Slim Initiative for Genomic Medicine — an unprecedented effort to accelerate progress in public health in Mexico and around the world through genomics. Established to investigate the genomic basis of cancer and type 2 diabetes across Mexico and Latin America, the Initiative is a $65 million project joining Mexico’s National Institute for Genomic Medicine, the National Autonomous University of Mexico, and the Broad Institute.

**The Klarman Family Foundation**
In 2012, the Boston-based Klarman Family Foundation provided a landmark $32.5 million grant to launch a new, collaborative pilot effort focused on deciphering how mammalian cells are wired, and how malfunctions in cellular processes give rise to disease. The newly launched Klarman Cell Observatory will allow the Broad to expand its understanding of how biological decisions are made in health and disease, paving the way for major treatment breakthroughs.

**The Merkin Family Foundation**
As the Institute’s first endowed fellowship program, the Merkin Institute Fellows fund provides sustained support for some of the Broad’s most promising and ambitious scientists. Established by the Merkin Family Foundation in 2012, this commitment builds on an earlier three-year gift from Dr. Merkin, which made possible the Richard Merkin Foundation for Stem Cell Research at the Broad Institute, launched in 2009.

**Donors**

<table>
<thead>
<tr>
<th>Anonymous (4)</th>
<th>Seth and Beth Klarman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agilent Technologies Foundation</td>
<td>Johanna L. Klein</td>
</tr>
<tr>
<td>Agilent Technologies, Inc.</td>
<td>Eric and Lori Lander</td>
</tr>
<tr>
<td>Airedale Health Foundation</td>
<td>Leonberger Health Foundation</td>
</tr>
<tr>
<td>Jill and David Altschuler</td>
<td>Arthur D. Levinson</td>
</tr>
<tr>
<td>Valerie C. Anastasio</td>
<td>Barbara V. McInnes</td>
</tr>
<tr>
<td>Dennis Ausiello, M.D.</td>
<td>Peter and Minou Palandjian</td>
</tr>
<tr>
<td>Drs. David Baltimore and Alice S. Huang</td>
<td>Sarah Pearson</td>
</tr>
<tr>
<td>Blavatnik Family Foundation</td>
<td>Julian H. Robertson, Jr.</td>
</tr>
<tr>
<td>Katherine and David Bradley</td>
<td>Paul Rotiroti</td>
</tr>
<tr>
<td>Leslie Burke</td>
<td>Stuart Schreiber and Mimi Packman</td>
</tr>
<tr>
<td>Sadiya Carr</td>
<td>Phillip and Ann Sharp</td>
</tr>
<tr>
<td>Kent and Liz Dauten</td>
<td>Ted and Vada Stanley</td>
</tr>
<tr>
<td>Joan Faubion, Ph.D.</td>
<td>Patty Stonessifer and Michael Kinsley</td>
</tr>
<tr>
<td>Alan Fein and Ellen Kolton</td>
<td>Kathan and Don Tracy</td>
</tr>
<tr>
<td>John B. Forrest, Jr.</td>
<td>Christopher and Diana Walsh</td>
</tr>
<tr>
<td>Patty and Paul Gannon</td>
<td>Chapman Walsh</td>
</tr>
<tr>
<td>Stephen and Wendy Gelman</td>
<td>The Wodecroft Foundation</td>
</tr>
<tr>
<td>Gerstner Family Foundation</td>
<td>The John F. MacDonald Fund for Pseudomonas Research in memory of John F. MacDonald</td>
</tr>
<tr>
<td>Todd and Martha Golub</td>
<td></td>
</tr>
<tr>
<td>Bill Helman</td>
<td></td>
</tr>
<tr>
<td>Irish Wolfhound Foundation</td>
<td></td>
</tr>
<tr>
<td>Irish Wolfhound Club of America</td>
<td></td>
</tr>
</tbody>
</table>
Corporations, Foundations, and Governmental Agencies That Have Provided Sponsored Research Support

- American Kennel Club, Canine Health Foundation
- Amgen, Inc.
- Bill & Melinda Gates Foundation
- Brain & Behavior Research Foundation
- Bristol-Myers Squibb Company
- Burroughs Wellcome Fund
- CHDI Foundation, Inc.
- Crohn’s and Colitis Foundation of America
- Damon Runyon Cancer Research Foundation
- Department of Agriculture
- Department of Defense
- Doris Duke Charitable Foundation
- Eli Lilly and Company
- The Esther A. & Joseph Klingenstein Fund, Inc.
- The European Bioinformatics Institute
- European Commission
- Fondation Leducq
- Foundation for Neurologic Diseases
- Galenea Corporation
- Human Frontier Science Program
- International SAE Consortium, LTD.
- Johnson & Johnson Pharmaceutical Research & Development, LLC
- Juvenile Diabetes Research Foundation
- The Leona M. and Harry B. Helmsley Charitable Trust
- Lilly USA, LLC
- The McKnight Endowment Fund for Neuroscience
- Merck Genome Research Institute
- Montreal Heart Institute
- Multi-Sponsor Consortium
- Multiple Myeloma Research Consortium
- National Institutes of Health
- National Science Foundation
- Nestlé Research Center
- Novartis Institutes for BioMedical Research
- Pfizer, Inc.
- Prostate Cancer Foundation
- SAIC-Frederick, Inc.
- Sanofi-Aventis U.S., LLC
- The Starr Foundation

FINANCIAL INFORMATION

Revenue by Source
FY2012 = $283.8M

- Foundations and Philanthropic Gifts $99.3M (35%)
- Industrial $11.4M (4%)
- Other Income $9.5M (3%)
- Fees and Services $8.5M (3%)
- Federal $156.1M (55%)

Broad Institute Operating Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2009</td>
<td>$221.7</td>
</tr>
<tr>
<td>FY2010</td>
<td>$258.0</td>
</tr>
<tr>
<td>FY2011</td>
<td>$299.0</td>
</tr>
<tr>
<td>FY2012</td>
<td>$283.8</td>
</tr>
</tbody>
</table>
Leadership

**Institutional Leadership**

- **Eric S. Lander**  
  President and Director
- **David Altshuler**  
  Chief Academic Officer and Deputy Director
- **Alan Fein**  
  Executive Vice President and Deputy Director

**Board of Scientific Counselors**

The Broad Institute’s Board of Scientific Counselors, appointed by the Board of Directors, meets annually to review the institute’s scientific progress over the past year and to provide advice on future scientific directions to the institute director and to the Board of Directors.

- **David Baltimore**  
  President *emeritus*, California Institute of Technology; Nobel Laureate
- **Carolyn Bertozzi**  
  Director of the Molecular Foundry, Lawrence Berkeley National Laboratory
- **Joseph Goldstein**  
  Professor of Molecular Genetics, UT Southwestern Medical Center; Nobel Laureate
- **David Haussler**  
  Director, Center for Biomolecular Science and Engineering, University of California, Santa Cruz
- **Richard Lifton**  
  Chairman, Department of Genetics, and Sterling Professor of Genetics, Yale University School of Medicine
- **Vicki Sato**  
  Professor of Management Practice, Harvard Business School; Former president, Vertex Pharmaceuticals
- **Charles Sawyers**  
  Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

**Board of Directors**

The Broad Institute’s Board of Directors includes representatives from our partner institutions, as well as leaders from the science, educational, and business communities.

- **Louis V. Gerstner, Jr., Chair**  
  Retired Chairman and CEO, IBM Corporation
- **Diana Chapman Walsh, Vice Chair**  
  President *emerita*, Wellesley College
- **David Baltimore**  
  President *emeritus*, California Institute of Technology; Nobel Laureate
- **Eli Broad**  
  Founder, The Broad Foundation
- **Drew Gilpin Faust**  
  President, Harvard University
- **Jeffrey S. Flier**  
  Dean of the Faculty of Medicine, Harvard Medical School
- **William Helman**  
  Partner, Greylock Partners
- **Seth A. Klarman**  
  President, The Baupost Group, LLC

**Institutional Leadership**

- **Eric S. Lander**  
  President and Director
- **Todd Golub**  
  Chief Scientific Officer
- **Diane MacDonald**  
  Chief Operating Officer and Treasurer

**Board of Directors**

- **Louis V. Gerstner, Jr., Chair**  
  Retired Chairman and CEO, IBM Corporation
- **Diana Chapman Walsh, Vice Chair**  
  President *emerita*, Wellesley College
- **David Baltimore**  
  President *emeritus*, California Institute of Technology; Nobel Laureate
- **Eli Broad**  
  Founder, The Broad Foundation
- **Drew Gilpin Faust**  
  President, Harvard University
- **Jeffrey S. Flier**  
  Dean of the Faculty of Medicine, Harvard Medical School
- **William Helman**  
  Partner, Greylock Partners
- **Seth A. Klarman**  
  President, The Baupost Group, LLC

**Institutional Leadership**

- **Eric S. Lander**  
  President and Director
- **Todd Golub**  
  Chief Scientific Officer
- **Diane MacDonald**  
  Chief Operating Officer and Treasurer

**Board of Directors**

- **Louis V. Gerstner, Jr., Chair**  
  Retired Chairman and CEO, IBM Corporation
- **Diana Chapman Walsh, Vice Chair**  
  President *emerita*, Wellesley College
- **David Baltimore**  
  President *emeritus*, California Institute of Technology; Nobel Laureate
- **Eli Broad**  
  Founder, The Broad Foundation
- **Drew Gilpin Faust**  
  President, Harvard University
- **Jeffrey S. Flier**  
  Dean of the Faculty of Medicine, Harvard Medical School
- **William Helman**  
  Partner, Greylock Partners
- **Seth A. Klarman**  
  President, The Baupost Group, LLC

**Institutional Leadership**

- **Eric S. Lander**  
  President and Director
- **Todd Golub**  
  Chief Scientific Officer
- **Diane MacDonald**  
  Chief Operating Officer and Treasurer

**Board of Directors**

- **Louis V. Gerstner, Jr., Chair**  
  Retired Chairman and CEO, IBM Corporation
- **Diana Chapman Walsh, Vice Chair**  
  President *emerita*, Wellesley College
- **David Baltimore**  
  President *emeritus*, California Institute of Technology; Nobel Laureate
- **Eli Broad**  
  Founder, The Broad Foundation
- **Drew Gilpin Faust**  
  President, Harvard University
- **Jeffrey S. Flier**  
  Dean of the Faculty of Medicine, Harvard Medical School
- **William Helman**  
  Partner, Greylock Partners
- **Seth A. Klarman**  
  President, The Baupost Group, LLC
Core Faculty Members

Core faculty members lead laboratories consisting of students, postdoctoral fellows, and scientific staff. These laboratories are similar in structure and membership to laboratories at academic institutions. However, rather than being embedded in a single department, core member laboratories are physically adjacent to scientists from other disciplines and work collaboratively with researchers both within and outside of the institute across a range of critical projects. In addition to their Broad appointments, all core faculty members hold faculty positions at MIT, Harvard, and/or one of the Harvard-affiliated hospitals.

David Altshuler, M.D., Ph.D.
Chief Academic Officer and Director of the Broad’s Program in Medical and Population Genetics, Altshuler is an international leader in the understanding and application of human genetics to the study of diseases such as type 2 diabetes, cancer, and heart attack.

Paul Blainey, Ph.D.
An expert in microfluidic systems for studies of individual molecules and cells, Blainey is leading the application of this technology to advance the understanding of DNA–protein interactions and genetic differences between cells.

Todd Golub, M.D.
Chief Scientific Officer and Director of the Broad’s Cancer Program, Golub has made fundamental advances in genomic approaches to cancer diagnosis and has pioneered new methods for drug discovery.

Myriam Heiman, Ph.D.
A pioneering neuroscientist with a background in genetics, biochemistry, and cell biology, Heiman is working to identify the defining features and vulnerabilities of the cells involved in neurodegenerative and psychiatric disease.

Deborah Hung, M.D., Ph.D.
A physician, chemist, and geneticist specializing in infectious disease, Hung, Director of the Broad’s Infectious Disease Program, combines chemical and genomic approaches to identify potential therapeutic targets for antimicrobial development.

Steven Hyman, M.D.
A distinguished neuroscientist and former provost of Harvard University, Hyman is the Director of the Broad’s Stanley Center for Psychiatric Research, where he oversees efforts to decrease the burden of psychiatric disease.

Eric Lander, Ph.D.
The founding Director of the Broad Institute, Lander served as one of the principal leaders of the Human Genome Project and has helped create many of the key tools of human genomics.

Aviv Regev, Ph.D.
A computational biologist and Director of the Klarman Cell Observatory, Regev’s research centers on deciphering the complex molecular circuits that control cells in health and disease.

Stuart Schreiber, Ph.D.
Director of the Broad’s Chemical Biology Program, Schreiber is a world leader in small-molecule science. His achievements, including the development of systematic ways to explore disease biology with small molecules, have dramatically advanced chemical biology.

Edward Scolnick, M.D.
Founding Director and Chief Scientist of the Stanley Center for Psychiatric Research, Scolnick helped bring psychiatric disease research into the biomedical age. Today, he spearheads the Institute’s efforts to understand and discover novel treatments for psychiatric diseases.

Feng Zhang, Ph.D.
A chemist and bioengineer, Zhang develops technologies to identify and understand the role of genetic variants in human health and disease. Zhang’s long-term goal is to develop novel therapeutic strategies for disease treatment.